Your browser doesn't support javascript.
loading
Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia.
Patel, Pratik A; DeGroote, Nicholas P; Jackson, Kasey; Cash, Thomas; Castellino, Sharon M; Jaggi, Preeti; Esbenshade, Adam J; Miller, Tamara P.
Afiliação
  • Patel PA; Division of Pediatric Hematology/Oncology, Emory University, Atlanta, Georgia, USA.
  • DeGroote NP; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Jackson K; Division of Pediatric Infectious Diseases, Emory University, Atlanta, Georgia, USA.
  • Cash T; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Castellino SM; Division of Pediatric Hematology-Oncology, Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.
  • Jaggi P; Division of Pediatric Hematology/Oncology, Emory University, Atlanta, Georgia, USA.
  • Esbenshade AJ; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Miller TP; Division of Pediatric Hematology/Oncology, Emory University, Atlanta, Georgia, USA.
Cancer ; 128(23): 4129-4138, 2022 12 01.
Article em En | MEDLINE | ID: mdl-36238979
BACKGROUND: Infections cause significant treatment-related morbidity during pediatric acute lymphoblastic leukemia/lymphoma (ALL/LLy) therapy. Fevers during periods without severe neutropenia are common, but etiologies are not well-described. This study sought to describe the bloodstream infection (BSI) and non-BSI risk in children undergoing therapy for ALL/LLy. METHODS: Demographic and clinical data were abstracted for febrile episodes without severe neutropenia at two children's hospitals. Treatment courses were stratified by intensity. Multivariate logistic regression evaluated characteristics associated with infection. RESULTS: There were 1591 febrile episodes experienced by 524 patients. Of these, 536 (34%) episodes had ≥1 infection; BSI occurred in 30 (1.9%) episodes. No BSIs occurred in episodes with a recent procedural sedation or cytarabine exposure. Presence of hypotension, chills/rigors, higher temperature, and infant phenotype were independently associated with BSI (p < .05). Of the 572 non-BSIs, the most common was upper respiratory infection (URI) (n = 381, 67%). Compared to episodes without infection, URI symptoms, higher temperature, absolute neutrophil count 500-999/µl, and evaluation during a low-intensity treatment course were more likely to be associated with a non-BSI (p < .05) and inpatient status was less likely to be associated with a non-BSI (p < .05). CONCLUSIONS: The BSI rate in pediatric patients with ALL/LLy and fever without severe neutropenia is low, but one-third of the time, patients have a non-BSI. Future research should test if the need for empiric antibiotics can be tailored based on the associations identified in this study.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Respiratórias / Bacteriemia / Sepse / Leucemia-Linfoma Linfoblástico de Células Precursoras / Linfoma / Neutropenia Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Respiratórias / Bacteriemia / Sepse / Leucemia-Linfoma Linfoblástico de Células Precursoras / Linfoma / Neutropenia Idioma: En Ano de publicação: 2022 Tipo de documento: Article